21520232

Source:http://linkedlifedata.com/resource/pubmed/id/21520232

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0205250, umls-concept:C0268274, umls-concept:C0598391
pubmed:issue	4
pubmed:dateCreated	2011-4-26
pubmed:abstractText	Novel recombinant human lysosomal ?-hexosaminidase A (HexA) was developed for enzyme replacement therapy (ERT) for Tay-Sachs and Sandhoff diseases, ie, autosomal recessive GM2 gangliosidoses, caused by HexA deficiency.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7707449
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Ccr1 protein, mouse, http://linkedlifedata.com/resource/pubmed/chemical/Hexosaminidase A, http://linkedlifedata.com/resource/pubmed/chemical/Hexosaminidase B, http://linkedlifedata.com/resource/pubmed/chemical/Mannose-6-Phosphate Isomerase, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR1, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1531-8249
pubmed:author	pubmed-author:AkeboshiHiromiH, pubmed-author:ChibaYasunoriY, pubmed-author:ItohKohjiK, pubmed-author:JigamiYoshifumiY, pubmed-author:KasaharaYoshikoY, pubmed-author:KawashimaIkuoI, pubmed-author:MatsuokaKazuhikoK, pubmed-author:MiyasakiEriE, pubmed-author:SakurabaHitoshiH, pubmed-author:TakiTakaoT, pubmed-author:TsujiDaisukeD, pubmed-author:YasuokaHirokoH
pubmed:copyrightInfo	Copyright © 2010 American Neurological Association.
pubmed:issnType	Electronic
pubmed:volume	69
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	691-701
pubmed:meshHeading	pubmed-meshheading:21520232-Animals, pubmed-meshheading:21520232-Disease Models, Animal, pubmed-meshheading:21520232-Dose-Response Relationship, Drug, pubmed-meshheading:21520232-Enzyme Replacement Therapy, pubmed-meshheading:21520232-Gangliosidoses, GM2, pubmed-meshheading:21520232-Hexosaminidase A, pubmed-meshheading:21520232-Hexosaminidase B, pubmed-meshheading:21520232-Humans, pubmed-meshheading:21520232-Injections, Intraventricular, pubmed-meshheading:21520232-Lysosomes, pubmed-meshheading:21520232-Mannose-6-Phosphate Isomerase, pubmed-meshheading:21520232-Mice, pubmed-meshheading:21520232-Mice, Knockout, pubmed-meshheading:21520232-Receptors, CCR1, pubmed-meshheading:21520232-Recombinant Proteins, pubmed-meshheading:21520232-Sandhoff Disease, pubmed-meshheading:21520232-Tay-Sachs Disease, pubmed-meshheading:21520232-Treatment Outcome, pubmed-meshheading:21520232-Yeasts
pubmed:year	2011
pubmed:articleTitle	Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis.
pubmed:affiliation	Department of Medicinal Biotechnology, Institute for Medicinal Research, Graduate School of Pharmaceutical Sciences, The University of Tokushima, Tokushima, Japan.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't